CJC-1295 (without DAC) vs Wolverine Stack
Well Studied vs Well Studied
synergistic Mechanism-based · 47% CJC-1295 (without DAC) and Wolverine Stack work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
CJC-1295 (without DAC) Wolverine Stack
Weight 3,367.97 Da N/A
Half-life 30 minutes - 2 hours —
Chain 30 amino acids N/A
Type GHRH analog Peptide blend
Key Benefits
CJC-1295 (without DAC)
01 Preserves natural GH pulsatility
02 Minimal side effects
03 No receptor desensitization
04 Precise GH release control
05 4x greater receptor affinity than native GHRH
Wolverine Stack
01 Complementary healing mechanisms
02 87.5% improvement in knee pain patients
03 Reduced inflammation and enhanced cell migration
04 Promotes angiogenesis and reduces scarring
Dosing Protocols
CJC-1295 (without DAC)
100-300mcg per injection / 2-3 times daily (morning, post-workout optional, bedtime)
Anti-Aging/Wellness 100mcg 2x daily (morning and bedtime)
Body Composition 100-150mcg 3x daily (morning, post-workout, bedtime)
Maximum GH Release 200mcg 2-3x daily with GHRP
Sleep Enhancement 100-200mcg Once at bedtime
Wolverine Stack
BPC-157: 250-500 mcg per dose + TB-500: 2-2.5 mg per dose / BPC-157: 1-2x daily; TB-500: 2x per week (typically Monday/Thursday or Tuesday/Friday)
General Recovery Protocol BPC-157: 250mcg 2x/day + TB-500: 2mg 2x/week BPC-157 daily, TB-500 twice weekly
Intensive Injury Recovery BPC-157: 500mcg 2x/day + TB-500: 2.5mg 2x/week BPC-157 daily, TB-500 twice weekly
Maintenance/Prevention Protocol BPC-157: 250mcg 1x/day + TB-500: 2mg 1x/week BPC-157 daily, TB-500 weekly
Side Effects
CJC-1295 (without DAC)
Generally well-tolerated at recommended doses
Temporary facial flushing/warmth (5-10 minutes post-injection)
Wolverine Stack
Not extensively documented in human studies
Generally well-tolerated in available research
Contraindications
Active cancer (due to growth-promoting effects)
Diabetic retinopathy
Severe kidney disease
Pregnancy or breastfeeding
ANY history of cancer or suspicious growths
Active malignancy or concurrent chemotherapy
Pregnancy or breastfeeding
Research Evidence
CJC-1295 (without DAC) Wolverine Stack
Status Well Studied Well Studied
References 5 studies 6 studies
Latest November 2024 2025
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.